A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application

Autor: Raymond Vanholder, Pierre Cochat, Andrzej Wiecek, Wim Van Biesen, Francis Verbeke, Gérard M. London, Elisabeth Lindley, Denis Fouque, Lucas Van Bortel
Přispěvatelé: Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Male
medicine.medical_specialty
medicine.drug_class
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
Population
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
urologic and male genital diseases
Nephropathy
Angiotensin Receptor Antagonists
Renal Dialysis
Diabetes mellitus
Medicine
Humans
Renal Insufficiency
Renal Insufficiency
Chronic
Intensive care medicine
Antihypertensive drug
education
Angiotensin Receptor Antagonists/*therapeutic use
Antihypertensive Agents
Aged
Transplantation
education.field_of_study
business.industry
Disease Management
Guideline
Middle Aged
medicine.disease
Hypertension/*drug therapy/prevention & control
Quality Improvement
3. Good health
Blood pressure
Nephrology
Hypertension
Practice Guidelines as Topic
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Female
Chronic/physiopathology/*therapy
Hemodialysis
business
Antihypertensive Agents/*therapeutic use
Kidney disease
Zdroj: Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation, Oxford University Press (OUP), 2014, 29 (3), pp.490-6. ⟨10.1093/ndt/gft321⟩
Europe PubMed Central
ISSN: 0931-0509
1460-2385
DOI: 10.1093/ndt/gft321⟩
Popis: International audience; Developing guidelines on a subject as broad as hypertension is difficult, especially when the guidance relates to hypertension in the chronic kidney disease (CKD) population. The Kidney Disease: Improving Global Outcomes Guideline Development Group has applied a rigorous methodology in reviewing all available evidence, and their recommendations are consistent with the evidence-based approach. As a result, the European Renal Best Practice endorses most of its recommendations. However, the Work Group feels that some additional advice could help clinicians in daily practice: (i) individualization of treatment should be taken into account, especially (cardiovascular) co-morbidities, age, gender and race; (ii) side-effects, such as postural dizziness should be monitored closely, particularly in elderly, diabetics and patients with arterial stiffness; (iii) the importance of salt restriction should not be neglected; (iv) although angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blocker (ARBs) remain a cornerstone in the management of hypertension, and especially cardiovascular protection, in some particular situations such as in advanced CKD and in patients without proteinuria, their role is less well defined; (v) as most CKD patients need more than one antihypertensive drug to achieve blood pressure control, the specific (renal) (dis)advantages of other classes than ACE-I or ARB should be taken into account.
Databáze: OpenAIRE
Externí odkaz: